Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Memantine and functional communication in Alzheimer's disease: Results of a 12-week, international, randomized clinical trial
Journal of Alzheimer's Disease, Volume 28, No. 1, Year 2012
Notification
URL copied to clipboard!
Description
Post hoc analyses suggest that memantine treatment may provide communication-related benefits in patients with Alzheimer's disease (AD). In this 12-week, international, randomized, double-blind, placebo-controlled trial of memantine (10 mg bid), the functional communication abilities of patients with AD (MMSE range: 10-19) were assessed using the Functional Linguistic Communication Inventory (FLCI; primary measure). Two combined subscales (Social Communication and Communication of Basic Needs) from the American Speech-Language-Hearing Association Functional Assessment of Communication Skills for Adults (ASHA FACS; secondary measure) were administered to caregivers. Treatment-emergent adverse events were also recorded. After 12 weeks, memantine-treated patients (n = 133) demonstrated a non-significant improvement on the FLCI (placebo: -0.6; memantine: 0.7; p = 0.070, LOCF) and a significant improvement on the ASHA FACS (placebo: -5.3; memantine: 0.5; p = 0.022), compared with placebo-treated patients (n = 124). Memantine had a low incidence of adverse events. In patients with moderate AD, memantine treatment improved functional communication, as recognized by caregivers. © 2012 IOS Press and the authors. All rights reserved.
Authors & Co-Authors
Saxton, Judith
United States, Pittsburgh
University of Pittsburgh School of Medicine
Hofbauer, Robert K.
United States, New York
Forest Laboratories, Inc
Woodward, Michael
Australia, Melbourne
Austin Health
Gilchrist, Nigel L.
New Zealand, Christchurch
The Princess Margaret Hospital, Christchurch
Potocnik, Felix C.V.
South Africa, Bellville
Flexivest 14 Research Centre
Hsu, Hai An
United States, New York
Forest Laboratories, Inc
Miller, Michael L.
United States, Chicago
Prescott Medical Communications Group
Pejović, Vojislav
United States, Chicago
Prescott Medical Communications Group
Graham, Stephen M.
United States, New York
Forest Laboratories, Inc
Perhach, James L.
United States, New York
Forest Laboratories, Inc
Statistics
Citations: 22
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.3233/JAD-2011-110947
ISSN:
13872877
e-ISSN:
18758908
Research Areas
Disability
Study Design
Randomised Control Trial
Cohort Study